References
- Mackman N. Triggers, targets and treatments for thrombosis. Nature.
2008;21;451(7181):914-8.
- Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous
thromboembolic disease: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;
133:454S–545S.
- ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major
contributor to the global disease burden. J Thromb Haemost.
2014;12(10):1580-90.
- Hammer Y, Iakobishvili Z, Hasdai D,et al. Guideline-Recommended
Therapies and Clinical Outcomes According to the Risk for Recurrent
Cardiovascular Events After an Acute Coronary Syndrome. J Am Heart
Assoc. 2018;18;7(18):e009885.
- Fang MC, Fan D, Sung SH, et al. Treatment and Outcomes of Acute
Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. Am
J Med. 2019;132(12):1450-1457.e1.
- Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated
with venous thromboembolism: a systematic review and Bayesian
meta-analysis. Lancet Haematol. 2020;7(8):e583-e593.
- Hao C, Sun M, Wang H, et al. Low molecular weight heparins and their
clinical applications. Prog Mol Biol Transl Sci. 2019;163:21-39.
- Pineo GF, Hull RD. Heparin and low-molecular-weight heparin in the
treatment of
venous
thromboembolism. Baillieres Clin Haematol. 1998;11(3):621-37.
- Xu Y, Wu W, Wang L, et al. Differential profiles of thrombin
inhibitors (heparin,
hirudin,
bivalirudin, and dabigatran) in the thrombin generation assay and
thromboelastography in vitro. Blood Coagul Fibrinolysis.
2013;24(3):332-8.
- Vanholder RC, Camez AA, Veys NM, et al. Recombinant hirudin: a
specific thrombin inhibiting anticoagulant for hemodialysis. Kidney
Int. 1994;45(6):1754-9.
- Zeymer U, Neuhaus KL. Hirudin and excess bleeding. Implications for
future use. Drug Saf. 1995;12(4):234-9.
- Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin.
Thromb Haemost. 2008;99(5):819-29.
- Wu Z, Guo Y, Liu Y, et al. Production technology of recombinant
neorudin expressed in E. coli. Beijing Univ. Technol. 2016;(42):
302–308.
- LIU Y, YU A, LIU N, et al. Determination of recombinant neorudin in
yeast fermentation supernatant by HPLC. Chin Med
Biotechnol.2017;12(05):391-396.
- Wu
Z, Yu A, Zhang C, et al. Preparation of low bleeding anticoagulant
fusion protein and its use. US Patent 20100113345A1. PCT No.
PCT/CN2007/ 03526. WO 2008/071081 A1. Filed December 11, 2007; issued
May 6, 2010.
- Zhang C, Yu A, Yuan B, et al. Construction and functional evaluation
of hirudin derivatives with low bleeding risk. Thromb Haemost.
2008;99(2):324-30.
- Dong X, Meng Z, Gu R, et al. Predicting the metabolic characteristics
of neorudin, a novel anticoagulant fusion protein, in patients with
deep vein thrombosis. Thromb Res. 2020;194:121-134.
- Fareed J, Walenga JM, Iyer L, et al. An objective perspective on
recombinant hirudin: a new anticoagulant and antithrombotic agent.
Blood Coagul Fibrinolysis. 1991;2(1):135-47.
- WANG W, XU X, ZHAO Z, et al. Anti-Thrombus Activity of a Novel
Anti-Thrombus Protein EPR- Hirudin. Chin Pharm J. 2013;48(02):111-115.
- Camez A. Refludan. First line of treatment for type II heparin-induced
thrombopenia. Presse Med. 1998;27 Suppl 2:28-30.
- Dong X, Meng Z, Jin J, et al. Development, validation, and clinical
pharmacokinetic application of ultra-performance liquid
chromatography/tandem mass spectrometry method for simultaneously
determining a novel recombinant hirudin derivative (Neorudin) and its
active metabolite in human serum. J Chromatogr B Analyt Technol Biomed
Life Sci. 2017;15;1063: 204-213.
- Dong X, Gu R, Zhu X,
et
al. Evaluating prodrug characteristics of a novel anticoagulant fusion
protein neorudin, a prodrug targeting release of hirudin variant
2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Eur J Pharm Sci. 2018;30;121:166-177
- Monreal M, Costa J, Salva P. Pharmacological properties of hirudin and
its derivatives. Potential clinical advantages over heparin. Drugs
Aging. 1996;8(3):171-82.
- Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin
(lepirudin) provides safe and effective anticoagulation in patients
with heparin-induced thrombocytopenia: a prospective study.
Circulation. 1999;5-12;99(1):73-80.
- Greinacher A, Lubenow N. Recombinant hirudin in clinical practice:
focus on lepirudin. Circulation. 2001;13;103(10):1479-84.
- Wakui M, Fujimori Y, Nakamura S, et al. Distinct features of bivalent
direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot
waveform analysis and enzyme kinetics in coagulation assays. J Clin
Pathol. 2019;72(12):817-824.
- Nowak G. Clinical monitoring of hirudin and direct thrombin
inhibitors. Semin Thromb Hemost. 2001;27(5):537-41.
- Di N, Squizzato A, Rutjes A, et al. Diagnostic accuracy of D-dimer
test for exclusion of venous thromboembolism: a systematic review.
Thromb Haemost. 2007;5(2):296-304.
- Bates S. D-dimer assays in diagnosis and management of thrombotic and
bleeding disorders. Semin Thromb Hemost. 2012;38(7):673-82.
- Riley R, Gilbert A, Dalton J, et al. Widely Used Types and Clinical
Applications of D-Dimer Assay. Lab Med. 2016;47(2):90-102.
- Gielen C, Grimbergen J, Klautz R, et al. Fibrinogen reduction and
coagulation in cardiac surgery: an investigational study. Blood Coagul
Fibrinolysis. 2015;26(6):613-20.
- Martini W. Coagulopathy by hypothermia and acidosis: mechanisms of
thrombin generation and fibrinogen availability. J Trauma.
2009;67(1):202-8; discussion 208-9.
- Despotis G, Skubas N, Goodnough L. Optimal management of bleeding and
transfusion in patients undergoing cardiac surgery. Semin Thorac
Cardiovasc Surg. 1999;11(2):84-104.
- Meyer BH, Luus HG, Müller FO, et al. The pharmacology of recombinant
hirudin, a new anticoagulant. S Afr Med J. 1990;78(5):268-70.
- Marbet GA. Verstraete M, Kienast J, et al. Clinical pharmacology of
intravenously administered recombinant desulfato hirudin (CGP 39393)
in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364-72.
- Verstraete M, Nurmohamed M. Kienast J, et al. Biologic effects of
recombinant hirudin (CGP 39393) in human volunteers. J Am Coli Cardiol
1993; 22: 1080-8.
- Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of
coagulation-inhibiting drugs. Expert Opin Drug Discov.
2017;12(12):1195-1205.